Diamedica Therapeutics Inc Stock Price, News & Analysis

DiaMedica Therapeutics (NASDAQ: DMAC) will present two abstracts at the American Heart Association 2022 International Stroke Conference in New Orleans from February 9-11, 2022. The abstracts focus on:

• Stroke Recurrence and Mortality with Recombinant Tissue Kallikrein Protein in the Remedy1 Phase 2 Trial
• Randomized, Double-blind, Placebo-controlled Study to Evaluate DM199 for Acute Ischemic Stroke (ReMEDy2 Trial)

Presentations will occur on February 10, 2022, from 12:30 PM to 1:15 PM at Poster Hall B2. Visit DiaMedica's website for more details.

DiaMedica Therapeutics has appointed Kirsten Gruis, M.D., as the new Chief Medical Officer. With 20 years of experience in neurology and drug development, Dr. Gruis aims to advance the company’s lead candidate, DM199, towards critical data for acute ischemic stroke. DM199 has shown promise in improving recovery outcomes and reducing recurrent strokes. An inducement grant of 160,000 stock options was also issued to Dr. Gruis, effective January 3, 2022, with an exercise price of $3.88 per share.

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced its participation in the LifeSci Partners 11th Annual Corporate Access Event, taking place virtually from January 5-7, 2022. The management team will engage in one-on-one meetings with investors during the event to discuss company developments. DiaMedica focuses on developing novel treatments for neurological disorders and kidney diseases, with lead candidate DM199 showing promising early clinical results. The company is advancing its pivotal ReMEDy Phase 2/3 trial for acute ischemic stroke and completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will have President and CEO Rick Pauls participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. One-on-one meetings will also be available. The presentation recording will be accessible starting on November 22, 2021, at 10:00 a.m. ET. DiaMedica is focused on developing DM199, a therapeutic for acute ischemic stroke and chronic kidney disease, with ongoing pivotal trials underway. More details can be found on their website.

DiaMedica Therapeutics (Nasdaq: DMAC) announced significant advancements in its programs with the first patient dosed in the Phase 2/3 ReMEDy2 trial for acute ischemic stroke (AIS). The FDA granted Fast Track Designation to DM199 for AIS treatment, enhancing the drug's development timeline. The company's recent $30 million private placement strengthened its balance sheet, raising cash to $48.1 million. R&D expenses increased slightly, totaling $2.3 million for Q3 2021, while G&A costs fell to $1.1 million.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, will participate in the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021. Management is available for one-on-one meetings, and interested investors can contact their Craig-Hallum representative to schedule. DiaMedica’s lead candidate, DM199, is aimed at treating acute ischemic stroke and chronic kidney disease. The company has initiated the ReMEDy Phase 2/3 trial for acute ischemic stroke and is completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced FDA approval to proceed with its Phase 2/3 ReMEDy2 trial for DM199, targeting acute ischemic stroke (AIS). The trial will now assess DM199's impact on stroke recovery and recurrence as independent primary endpoints. This decision is based on prior clinical data showing no recurrent strokes in DM199-treated patients versus a 13.3% rate in the placebo group. Stroke recurrence is significant, with 25% of U.S. strokes being recurrent, highlighting the urgent need for better treatments.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2021 financial results post-market on November 10, 2021. A conference call is scheduled for November 11, 2021, at 7:00 AM CT to discuss the results and provide a business update. The call can be accessed via telephone or webcast, with a replay available until November 18, 2021. The company focuses on neurological disorders and kidney diseases, with its lead candidate, DM199, aimed at treating acute ischemic stroke and chronic kidney disease.

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced that late-breaking data from its Phase 2 REDUX trial of DM199 for chronic kidney disease will be presented at the American Society of Nephrology's Kidney Week meeting. The presentation will include an update to interim data announced in June 2021. The session is set for November 4, 2021, highlighting ongoing research into DM199's effectiveness, a recombinant form of KLK1, which may address critical health issues including stroke and kidney disease.